Newsroom | 1364 results

CHICAGO--(BUSINESS WIRE)--New ComPsych data shows the "new normal" in employee leaves post-pandemic as well as the impact of behavioral health services on leave duration...

MIAMI--(BUSINESS WIRE)--Wenn sich die Regierungen in Genf im Rahmen der zweiten Intergovernmental Working Group (IGWG) Tagung zum Pathogen Access and Benefit Sharing (PABS) Anhang in der nächsten Woche versammeln, steht viel auf dem Spiel. Diese Verhandlungen werden zeigen, ob die Mitgliedstaaten die Entschlossenheit haben, sinnvolle Schritte zu unternehmen, um die unakzeptablen Ungerechtigkeiten, die durch die COVID-19-Pandemie offenbar wurden, zu beseitigen — indem das kollektive Interesse üb...

MIAMI--(BUSINESS WIRE)--Les enjeux sont considérables pour les gouvernements qui se réuniront à Genève la semaine prochaine, à l'occasion de la deuxième session du groupe de travail intergouvernemental (IGWG, Intergovernmental Working Group) portant sur l'annexe consacrée à l'accès aux agents pathogènes et au partage des avantages (PABS, Pathogen Access and Benefit Sharing). Ces négociations permettront de déterminer si les États membres sont résolus à prendre des mesures sérieuses pour corrige...

MIAMI--(BUSINESS WIRE)--As governments gather in Geneva for the second Intergovernmental Working Group (IGWG) session on the Pathogen Access and Benefit Sharing (PABS) Annex next week, the stakes are high. These negotiations will determine whether Member States have the resolve to take meaningful steps to correct the unacceptable inequities laid bare by the COVID-19 pandemic—by placing the collective interest above narrow self-interest and industry greed. Member States now face a compressed tim...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19. The pr...

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will share 17 scientific presentations from across its anti-infective programs at IDWeek 2025 (October 19-22, 2025) in Atlanta, Georgia. Presentations at IDWeek will feature new real-world evidence from three separate analyses from PROVE (Retrospective Cefiderocol Chart Review), the largest observational study to...

DUBLIN--(BUSINESS WIRE)--The "mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Indication (Metabolic & Genetic Diseases), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033 ()" report has been added to ResearchAndMarkets.com's offering. The global mRNA therapeutics contract development & manufacturing organization market size is estimated to reach USD 14.75 billion by 2033, expanding at a CA...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Shionogi Inc., a New Jersey-based subsidiary of Shionogi, for ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622), an investigational oral antiviral for the prevention of COVID-19 following exposure to an infected individua...

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome. Findings were presented at the 36th International Epil...

IRVINE, Calif.--(BUSINESS WIRE)--Dr. Young brings an extraordinary depth of experience in vaccine science, immunology, and pharmaceutical development, with more than 40 years of leadership across academia, government initiatives, and the biotechnology industry. He has been a driving force in advancing vaccine innovation, regulatory strategy, and global health impact. He was involved in the Operation Warp Speed effort, the U.S. government’s coordinated initiative to accelerate the development, m...